Consensus on medical treatment of non-small-cell lung cancer - Update 2004

Lung Cancer

Volumn 50, Issue 1, 2005, Pages 129-137

  Zielinski, C C ^a   Krainer, M ^a   Pirker, R ^a   Tomek, S ^a   Zochbauer Muller S ^a   Beinert, T ^b   Crawford, J ^c   Fischer, J R ^d   Georgoulias, V ^e   Gridelli, C ^f   Hirsch, F ^g   Jassem, J ^h   Herold, Ch ⁱ   Kosmidis, P ^j   Krzakowski, M ^h   Manegold, Ch ^k   Pujol, J L ^l   Thatcher, N ^m   Van Zandwijk, N ⁿ   Zwitter, M ^o  

^a UNIVERSITY OF VIENNA   (Austria)

^b Wartenberg Clinic   (Germany)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Klinik Lowenstein   (Germany)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF COLORADO   (United States)

^h Department of Oncology and Radiotherapy ^*  (Poland)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j HYGEIA HOSPITAL   (Greece)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l HÔPITAL ARNAUD DE VILLENEUVE   (France)

^m CRC Department of Medical Oncology   (United Kingdom)

ⁿ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^o INSTITUTE OF ONCOLOGY   (Slovenia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CANCER VACCINE; CARBOPLATIN; CISPLATIN; COLONY STIMULATING FACTOR; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROPOIETIN; GEFITINIB; GEMCITABINE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PEMETREXED; PLATINUM; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANEMIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEBRILE NEUTROPENIA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMAGING; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 24744436839     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.05.014     Document Type: Conference Paper

References (60)

1. C.C. Zielinski, T. Beinert, J. Crawford, L. Crino, J.R. Fischer, and V. Georgoulias Consensus on medical treatment of non-small-cell lung cancer Lung Cancer 38 Suppl 3 2002 1 85
2. E.M. Toloza, L. Harpole, and D.C. McCrory Noninvasive staging of non-small-cell lung cancer: a review of the current evidence Chest 123 2003 137S 146S
3. M. Cymbalista, A. Waysberg, C. Zacharias, Y. Ajavon, M. Riquet, and G. Rebibo CT demonstration of the 1996 AJCC-UICC regional lymph node classification for lung cancer staging Radiographics 19 1999 899 900 poster
4. B. Mayr, M. Lenhard, U. Fink, S.H. Heywang-Kobrunner, L. Sunder-Plassmann, and W. Permanetter Preoperative evaluation of bronchogenic carcinoma: value of MR in T- and N-staging Eur J Radiol 14 1992 245 251
5. Y. Ohno, H. Hatabu, D. Takenaka, T. Higashino, H. Watanabe, and C. Ohbayashi Metastases in mediastinal and hilar lymph nodes in patients with non-small-cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging Radiology 231 2004 872 879
6. Halpern B, Schiepers C, Weber W, Crawford T, Fueger B, Silverman D, et al. Pre-Surgical staging of non-small-cell lung cancer: a comparison between PET, Hardware PET/CT and Software Image Fusion. EJNM, submitted for publication.
7. PORT Meta-analysis Trialists Group Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials Lancet 352 1998 257 263
8. S. Burdett, and L. Stewart Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis Lung Cancer 47 2005 81 83
9. Non-small-cell Lung Cancer Collaborative Group Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
10. R. Arriagada, B. Bergman, A. Dunant, T. Le Chevalier, J.P. Pignon, and J. Vansteenkiste Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
11. T.L. Winton, R. Livingston, D. Johnson, J. Rigas, Y. Cormier, and C. Butts A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) intergroup JBR.10 Proc Am Soc Clin Oncol 22 2004 7018
12. G.M. Strauss, J. Herndon, M.A. Maddaus, D.W. Johnstone, E.A. Johnson, and D.M. Watson Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633 Proc Am Soc Clin Oncol 22 2004 7019
13. G.V. Scagliotti, R. Fossati, V. Torri, L. Crino, G. Giaccone, and G. Silvano Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer J Natl Cancer Inst 95 2003 1453 1461
14. J.A. Roth, F. Fossella, R. Komaki, M.B. Ryan, J.B. Putnam Jr, and J.S. Lee A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer J Natl Cancer Inst 86 1994 673 680
15. R. Rosell, J. Gomez-Codina, C. Camps, J. Maestre, J. Padille, and A. Canto A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 330 1994 153 158
16. A. Depierre, B. Milleron, D. Moro-Sibilot, S. Chevret, E. Quoix, and B. Lebeau Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer J Clin Oncol 20 2002 247 253
17. J. Jassem Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer Lancet Oncol 2 2001 335 342
18. K. Furuse, M. Fukuoka, M. Kawahara, H. Nishikawa, Y. Takada, and S. Kudoh Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
19. P. Zatloukal, L. Petruzelka, M. Zemanova, L. Havel, F. Janku, and L. Judas Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small-cell lung cancer: a randomized study Lung Cancer 46 2004 87 98
20. W. Curran, C. Scott, C. Langer, R. Komaki, J. Lee, and S. Hauser Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage NSCLC: RTOG 9410 (abstrakt) Proc Am Soc Clin Oncol 22 2003 621
21. D.G. Pfister, D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, and S. Baker Jr American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
22. D.R. Gandara, J. Crowley, R.B. Livingston, E.A. Perez, C.W. Taylor, and G. Weiss Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group J Clin Oncol 11 1993 873 878
23. P.A. Bunn Jr., and K. Kelly New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions Clin Cancer Res 4 1998 1087 1100
24. R.M. Rudd, N.H. Gower, L.E. James, W. Gregory, T. Eisen, and S.M. Lee Phase III randomized comparison of gemcitabine and carboplatin with Mitomycin, Iphosphamide and Cisplatin in advanced non-small-cell lung cancer Proc Am Soc Clin Oncol 21 2002 1164
25. K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 22 2004 3852 3859
26. T. Le Chevalier, G. Scagliotti, R. Natale, S. Danson, R. Rosell, and R. Stahel Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes Lung Cancer 47 2005 69 80
27. P.A. Bunn Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20 2002 23S 33S
28. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
29. I.E. Smith, M.E. O'Brien, D.C. Talbot, M.C. Nicolson, J.L. Mansi, and T.F. Hickish Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol 19 2001 1336 1343
30. M.A. Socinski, M.Q. Baggstrom, and T.A. Hensing Duration of chemotherapy in advanced, metastatic non-small-cell lung cancer Clin Adv Hematol Oncol 1 2003 33 38
31. M.A. Socinski, M.J. Schell, A. Peterman, K. Bakri, S. Yates, and R. Gitten Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343
32. V. Georgoulias, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, and M. Veslemes Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 2001 1478 1484
33. J.H. Schiller Platin or no platin? That is the question J Clin Oncol 21 2003 3009 3010
34. P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, and J. Boukovinas Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial J Clin Oncol 20 2002 3578 3585
35. V. Alberola, C. Camps, M. Provencio, D. Isla, R. Rosell, and C. Vadell Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial J Clin Oncol 21 2003 3207 3213
36. C. Delbaldo, N. Syz, S. Michiels, T. Le Chevalier, and J.P. Pignon Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma: a metaanalysis of the literature Proc Am Soc Clin Oncol 22 2003 2507
37. R.C. Lilenbaum, J.E. Herndon 2nd, M.A. List, C. Desch, D.M. Watson, and A.A. Miller Single agent versus combination chemotherapy in advanced non-small-cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness Proc Am Soc Clin Oncol 21 2002 2
38. M.Q. Baggstrom, M.A. Socinski, T.A. Hensing, and C. Poole Addressing the optimal number of cytotoxic agents in stage IIIA/IV non-small-cell lung cancer: a metaanalysis of the published literature Proc Am Soc Clin Oncol 22 2003 2510
39. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, and V. Miller Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
40. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, and C. Manegold Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
41. R.S. Herbst, D. Prager, R. Hermann, V. Miller, L. Fehrenbacher, and P. Hoffman TRIBUTE - a phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer Proc. Am Soc Clin Oncol 23 2004 7011
42. U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, and U. Brennscheidt Results of a phase III trial of erlotinib comined with cisplatin and gemcitabine chemotherapy in advanced non-small-cell lung cancer Proc Am Soc Clin Oncol 23 2004 7010
43. C. Sederholm Gemcitabine versus gemcitabine/carboplatin in advanced non-small-cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group Semin Oncol 29 2002 50 54
44. The Elderly Lung Cancer Vinorelbine Italian Study Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer J Natl Cancer Inst 91 1999 66 72
45. C. Gridelli, P. Maione, G. Colantuoni, and A. Rossi Chemotherapy of non-small-cell lung cancer in elderly patients Curr Med Chem 9 2002 1487 1495
46. C. Gridelli, A. Ardizzoni, T. Le Chevalier, C. Manegold, F. Perrone, and N. Thatcher Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of a European Experts Panel Ann Oncol 15 2004 419 426
47. F.A. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, and M. O'Rourke Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
48. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, and J. von Pawel Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
49. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
50. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr, D. Prager, and C.P. Belani Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
51. F.A. Shepherd, J. Pereira, T.E. Ciuleanu, T.J. Lynch Jr, D. Prager, and C.P. Belani A randomised placebo-controlled trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Trial Group (NCIC CTG) trial Proc Am Soc Clin Oncol 22 2004 7022
52. G.H. Lyman, N.M. Kuderer, and B. Djulbegovic Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis Am J Med 112 2002 406 411
53. A. Pagliuca, P.A. Carrington, R. Pettengell, S. Tule, and J. Keidan Guidelines on the use of colony-stimulating factors in haematological malignancies Br J Haematol 123 2003 22 33
54. H. Ozer, J.O. Armitage, C.L. Bennett, J. Crawford, G.D. Demetri, and P.A. Pizzo 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 2000 3558 3585
55. F.R. Hirsch, W.A. Franklin, A.F. Gazdar, and P.A. Bunn Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology Clin Cancer Res 7 2001 5 22
56. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
57. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
58. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, and I. Sarkaria EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
59. F. Cappuzzo, F.R. Hirsch, E. Rossi, S. Bartolini, G.L. Ceresoli, and L. Bemis Epidermal growth factor receptor gene copynumber, gene mutations and protein level predict outcome to gefitinib therapy in advanced non-small-cell lung cancer J Natl Cancer Inst 97 9 2005 643 655
60. F.R. Hirsch, W.A. Franklin, S.E. Witta, B. Helfrich, R. Lapadat, and C.D. Coldren Defining gefitinib sensitivity/resistance in non-smal-cell lung cancer (NSCLC) cell lines by affymetrix gene arrays Proc Am Soc Clin Oncol 23 2004 7027